A raft of data on licensed and investigational multiple sclerosis treatments will be unveiled by Novartis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, which opens today (October 10) in Lyon, France.
These include 58 data presentations on its oral treatment Gilenya (fingolimod) and on the company’s investigational compounds BAF312 (siponimod) and AIN457 (secukinumab) – an antibody against interleukin-17A, in relapsing-remitting MS.
The Swiss major is unveiling results from the Phase III FREEDOMS II study, showing that Gilenya reduces magnetic resonance imaging inflammatory lesion activity versus placebo, as well as long-term safety data. Betsy Garofalo, global head of neuroscience development at Novartis Pharma, said that along with the new data reinforcing the efficacy and safety profile of Gilenya, "we’re pleased to present positive results for our investigational MS compounds BAF312 (siponimod) and AIN457 (secukinumab)”.
Results from the siponimod Phase II BOLD study in RRMS will be presented, in addition to pre-clinical data demonstrating that BAF312 reaches the central nervous system, suggesting potential for direct CNS effects that may be relevant for treatment of secondary-progressive MS (SPMS). These data support the move to a Phase III study of BAF312 in SPMS starting later this year, says Novartis.
According to the company, results from a Phase II study show that treatment with siponimod, an oral, selective modulator of the sphingosine 1 phosphate receptor subtypes 1 and 5, leads to early MRI benefits in RRMS patients.
There will also be a proof-of-concept presentation in the late-breaking session on secukinumab for RRMS.